GlassScriptPhysician profile
Abid A Rizvi
NPI 1255582540
$1,896.43
in general payments reported to CMS, 2019-2025
20 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $17.13 · 2021: $162 · 2022: $55.06 · 2023: $245 · 2024: $727 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $45.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.13 |
| Education | $45.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $346.54 | 2019-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $209.01 | 2019-2024 | Jynarque |
| Akebia Therapeutics INC | $167.95 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $136.93 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.43 | 2023-2024 | Benlysta |
| Novo Nordisk INC | $133.96 | 2022-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $131.37 | 2021-2024 | Rayaldee |
| Baxter Healthcare | $101.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.32 | 2021-2024 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $88.33 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $81.24 | 2024-2025 | |
| Travere Therapeutics, INC. | $67.99 | 2023-2025 | |
| Ardelyx, INC. | $60.94 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $25.28 | 2021 | |
| Cormedix INC. | $24.68 | 2024 | Defencath |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.15 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $19.96 | 2021 | |
| Csl Behring | $17.25 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.38 | 2022 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.